Here's what analysts were saying about Shire's takeover of NPS Pharmaceuticals.
AmerisourceBergen announced on Jan. 12 that it inked a deal to acquire Boise, Idaho-based MWI Veterinary Supply for $2.5 billion.
Foundation Medicine (FMI) shares are rising after Roche Holding (RHHBY) announced that it was purchasing a 56.3% stake in the company.
Included in Bienaime's investor presentation is two slides making a direct data comparison between BioMarin's (soon to be) Duchenne muscular dystrophy drug drisapersen and Sarepta's competing DMD drug eteplirsen.
The timing of the Afrezza commercial launch is still a mystery following Sanofi's presentation.
Celgene CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020.
NPS Pharmaceuticals (NPSP) shares are climbing after the company agreed to be purchased by Shire plc for $5.2 billion.
Irish drugmaker Shire PLC said Sunday it will pay $5.2 billion to acquire NPS Pharmaceuticals, which specializes in drugs for rare conditions.
Roche seeks as much as 56% of Mass.-based Foundation Medicine to gain insights it can use in the development of cancer drugs, while AC Immune attracts the attention of Janssen.
The company presents at the J.P. Morgan Healthcare Conference on Thursday.
The Dublin company bounces back three months after the collapse of its own $49 billion takeover by AbbVie.
European markets rebound on merger activity in the pharma industry and activity in the airline world.
Lung cancer is a larger commercial market opportunity for Bristol's Opdivo and Merck's Keytruda.
The company announced its 2015 business outlook on Sunday ahead of its presentation at the J.P. Morgan Healthcare Conference.
Roche's $1 billion-plus investment in Foundation Medicine aims to expand use of genetic testing to develop new, more effective drugs.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV